Company: DMAAR
Filing Date: 2025-11-18
Form Type: 10-Q
Source: 0001213900-25-112096
Chunk: 71

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-11-18
Form: 10-Q
Item: Part I, Item 8
Chunk 71
---
481  
    $3,783,124  
    $1,944,561 
  
    Denominator: 

    Weighted-average shares outstanding 
     23,000,000  
     10,517,143  
     20,336,996  
     10,453,407 
  
    Diluted
    net income per ordinary share 
    $0.07  
    $0.07  
    $0.19  
    $0.19 

    Three Months Ended September 30, 2024  
    For The Period from
 May 23, 2024  (Inception) through September 30, 2024 

    Redeemable  
    Non-Redeemable  
    Redeemable  
    Non-Redeemable 
  
    Basic and diluted net loss per share: 

    Numerator: 

    Allocation of net loss 
    $—  
    $(144,928) 
    $—  
    $(199,859)
  
    Denominator: 

    Weighted-average shares outstanding 
     —  
     8,571,429  
     —  
     8,571,429 
  
    Basic and diluted net loss per ordinary share 
    $—  
    $(0.02) 
    $—  
    $(0.02)

Recent
Accounting Standards 

In
November 2024, the FASB issued Accounting Standards Update (“ASU”) 2024-03, “Income Statement-Reporting Comprehensive
Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses”, requiring public entities
to disclose additional information about specific expense categories in the notes to the financial statements on an interim and annual
basis. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods beginning after December
15, 2027, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2024-03. 

Management
does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, would have a material
effect on the Company’s financial statement.

11

DRUGS
MADE IN AMERICA ACQUISITION CORP.

NOTES
TO FINANCIAL